BAKER DONELSON CENTER• SUITE 800• 211 COMMERCE STREET• NASHVILLE, TENNESSEE 37201 615.726.5600• bakerdonelson.com
TONYA MITCHEM GRINDON, SHAREHOLDER
Direct Dial: 615.726.5607
Direct Fax: 615.744.5607
E-Mail Address: tgrindon@bakerdonelson.com
January 27, 2017
Via Electronic Mail
MCCANNJ@sec.gov
United States Securities and Exchange Commission
Mail Stop 4546
100 F Street, N.E.
Washington, D.C. 20549
Attn.: Mr. Joseph McCann
| Re: | Provectus Biopharmaceuticals, Inc. |
Dear Mr. McCann:
This letter is to confirm that Provectus Biopharmaceuticals, Inc. (the “Company”) will file a final prospectus (the “Final Prospectus”) under Rule 424(b) promulgated under the Securities Act of 1933, as amended, in connection with the Company’s offering (the “Rights Offering”) of non-transferable subscription rights (the “Rights”) to holders of the Company’s common stock and holders of the Company’s class of warrants with an exercise price of $0.85 expiring June 19, 2020, for units (“Units”) issuable upon exercise of the Rights before distributing the Rights to such holders. The Company hereby agrees that the Final Prospectus will contain the subscription price per Unit being offered in the Rights Offering.
| Best regards, |
BAKER, DONELSON, BEARMAN, CALDWELL & BERKOWITZ, PC |
| /s/ Tonya Mitchem Grindon |
| Tonya Mitchem Grindon, Shareholder |
TZG:psa
| ALABAMA•FLORIDA• GEORGIA• LOUISIANA• MARYLAND• MISSISSIPPI• SOUTH CAROLINA• TENNESSEE TEXAS•VIRGINIA• WASHINGTON, D.C. |